Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Investors are preparing for potential market turbulence surrounding the US presidential election, with demand for options increasing earlier than in ...